CRISPR and Cas Genes Market- An Overview
CRISPR-Cas systems are effective and effortlessly programmable nucleic acid-targeting tools. The use of CRISPR-Cas systems in bacterial activities, increase in research and development expenditure by governments in the fields of genome editing, rise in the presence of genetic diseases, and the use of CRISPR technology to advance crop production have been the key drivers of the CRISPR and Cas genes market worldwide.
Some of the potential applications of CRISPR-Cas systems include immunization of cultures, self-targeted cell destruction, and engineering of metabolic pathways for better biochemical synthesis. The use of CRISPR-Cas systems, in recent times, has not been merely restricted to research and therapeutic development and has extended to areas such as the engineering of industrial microbes and the breeding of plants and animals.
One benefit of using CRISPR technology is that it permits genetic material to be added or removed at specific locations in the genome. CRISPR technology has been progressively employed in the study of human diseases, which include the likes of cystic fibrosis, Barth syndrome consequences on the heart, hemophilia, and Duchenne muscular dystrophy.
The introduction of the CRISPR/Cas9 technology can be termed as a revolutionary step in the biomedical research field. The objective behind the use of CRISPR/Cas9 is to fasten the application of the technologies in the treatment of several genetic disorders.
Europe and North America held a combined total of 71% share in the overall CRISPR and Cas genes market in 2017. An increase in research activities, technological innovations are anticipated to drive the CRISPR and Cas genes market in both regions in future. In Europe, specifically, the rise in the acceptance of technology and the presence of important market players are likely to fuel the growth of the CRISPR and Cas genes market, in future.
The CRISPR and Cas genes market faces its own set of challenges as well. Fewer skilled professionals, as well as ethical concerns about CRISPR, could prove restrictive to the growth of the global CRISPR and Cas genes market.
Global CRISPR and Cas Genes Market – Snapshot
CRISPR-Cas systems are efficient and easily programmable nucleic acid-targeting tools, with usage expanding beyond research and therapeutic development to precision breeding of plants and animals and engineering of industrial microbes. CRISPR-Cas systems have potential applications in microbial engineering including bacterial strain typing, immunization of cultures, autoimmunity or self-targeted cell killing, and the engineering or control of metabolic pathways for improved biochemical synthesis. The global CRISPR and Cas genes market was valued at US$ 1,451.6 Mn in 2017 and is anticipated to reach US$ 7,234.5 Mn by 2026, expanding at a CAGR of 20.1% from 2018 to 2026.
Usage of CRISPR-Cas systems in bacteria, rise in government spending on research and development of genome editing, increase in incidence of genetic disorders, and usage of CRISPR/Cas9 technology to improve crop production drive the global CRISPR and Cas genes market. Genome editing technologies such as CRISPR/Cas9 is a revolutionary step in the field of biomedical research. Application of CRISPR/Cas9 focusing on somatic cell genome editing program is aimed at accelerating the use of these technologies to treat various genetic disorders. However, ethical issues concerning CRISPR and lack of skilled professionals restrain the global CRISPR and Cas genes market.
The global CRISPR and Cas genes market has been segmented based on product type, application, end-user, and region. In terms of product type, the global market has been bifurcated into vector-based Cas and DNA-free Cas. Based on application, the global CRISPR and Cas genes market has been classified into genome engineering, disease models, functional genomics, knockout/activation, and others. In terms of end-user, the global market has been categorized into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. Based on region, the global CRISPR and Cas genes market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
In terms of product type, the vector-based Cas segment dominated the global market in 2017, accounting for 62.1% share. Vector-based Cas expression systems are useful for researchers who focus on enriching Cas9-expressing cells or strive to establish a stable cell line. Vector-based Cas is also available with an inducible promoter that supports the creation of stable cell lines with minimal background expression, or for temporal control over Cas9 expression for wide-ranging experimental applications. The DNA-free Cas segment is anticipated to gain market share during the forecast period. Advantages such as gene editing with DNA-free CRISPR-Cas9 components to reduce potential off-targets and potential usage of CRISPR-Cas9 gene editing to find correlations with human diseases in model systems drive the segment.
Based on application, the genome engineering segment dominated the global CRISPR and Cas genes market in 2017. CRISPR technology allows genetic material to be added, removed, or altered at particular locations in the genome. Cas9 mRNA or purified Cas9 protein is the source for Cas9 nuclease expression in genome engineering experiments. Genomic engineering is the synthetic assembly of complete chromosomal DNA that is more or less derived from natural genomic sequences. Disease models was the second largest segment of the global market. CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5 and programmed death-1 gene. This technology has been increasingly applied in the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, β-thalassemia, and cystic fibrosis.
In terms of end-user, the biotechnology & pharmaceutical companies segment dominated the global CRISPR and Cas Gene market in 2017. Adoption of CRISPR technology by pharmaceutical & biotechnology companies through strategic partnerships with innovators drives the segment. In 2017, CRISPR Therapeutics established a joint venture called Casebia Therapeutics LLP with Bayer HeathCare and its subsidiaries. Academic & government research institutes was the second largest segment of the global market.
Based on region, North America and Europe dominated the global CRISPR and Cas genes market in 2017, accounting for 71% share. Rise in research activities and technological advancements are expected to drive the CRISPR and Cas genes market in the regions during the forecast period. In 2016, a human clinical trial was initiated for the use of CRISPR to treat diseases in the U.S. Increase in adoption of technology and presence of key players in the region are likely to accelerate the growth of the CRISPR and Cas genes market in Europe during the forecast period.
Major players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. These players adopt organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.
The global CRISPR and Cas genes market has been segmented as follows:
|
Product |
|
|
Application |
|
|
End-user |
|
|
Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global CRISPR and Cas Genes Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.2.1. Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast, 2016–2026
4.2.2. Global CRISPR and Cas Genes Market Outlook
4.2.3. Evolution of CRISPRs
4.2.4. Research institutes involved in CRISPR Research
4.2.5. CRISPR: Funding & Investment
4.2.7. Mergers and Acquisitions
4.3. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
5. Global CRISPR and Cas Genes Market Analysis and Forecasts, by Product
5.1. Introduction & Definition
5.2. Market Value Forecast, by Product, 2016–2026
5.2.1. Vector-based Cas
5.2.2. DNA-free Cas
5.3. Market Attractiveness, by Product
6. Global CRISPR and Cas Genes Market Analysis and Forecasts, by Application
6.1. Introduction & Definition
6.2. Market Value Forecast, by Application, 2016–2026
6.2.1. Genome Engineering
6.2.2. Disease Models
6.2.3. Functional Genomics
6.2.4. Knockdown/activation
6.2.5. Others
6.3. Market Attractiveness, by Application
7. Global CRISPR and Cas Genes Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Market Value Forecast, by End-user, 2016–2026
7.2.1. Biotechnology & Pharmaceutical Companies
7.2.2. Academic & Government Research Institutes
7.2.3. Contract Research Organizations
7.3. Market Attractiveness, by End-user
8. Global CRISPR and Cas Genes Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America CRISPR and Cas Genes Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Product, 2016–2026
9.2.1. Vector-based Cas
9.2.2. DNA-free Cas
9.3. Market Value Forecast, by Application, 2016–2026
9.3.1. Genome Engineering
9.3.2. Disease Models
9.3.3. Functional Genomics
9.3.4. Knockdown/activation
9.3.5. Others
9.4. Market Value Forecast, by End-user, 2016–2026
9.4.1. Biotechnology & Pharmaceutical Companies
9.4.2. Academic & Government Research Institutes
9.4.3. Contract Research Organizations
9.5. Market Value Forecast, by Country, 2016–2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By Application
9.6.3. By End-user
9.6.4. By Country
10. Europe CRISPR and Cas Genes Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Product, 2016–2026
10.2.1. Vector-based Cas
10.2.2. DNA-free Cas
10.3.Market Value Forecast, by Application, 2016–2026
10.3.1. Genome Engineering
10.3.2. Disease Models
10.3.3. Functional Genomics
10.3.4. Knockdown/activation
10.3.5. Others
10.4.Market Value Forecast, by End-user, 2016–2026
10.4.1. Biotechnology & Pharmaceutical Companies
10.4.2. Academic & Government Research Institutes
10.4.3. Contract Research Organizations
10.5.Market Value Forecast, by Country/Sub-region, 2016–2026
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country/Sub-region
11. Asia Pacific CRISPR and Cas Genes Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Product, 2016–2026
11.2.1. Vector-based Cas
11.2.2. DNA-free Cas
11.3.Market Value Forecast, by Application, 2016–2026
11.3.1. Genome Engineering
11.3.2. Disease Models
11.3.3. Functional Genomics
11.3.4. Knockdown/activation
11.3.5. Others
11.4.Market Value Forecast, by End-user, 2016–2026
11.4.1. Biotechnology & Pharmaceutical Companies
11.4.2. Academic & Government Research Institutes
11.4.3. Contract Research Organizations
11.5.Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Japan
11.5.2. China
11.5.3. India
11.5.4. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Latin America CRISPR and Cas Genes Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Product, 2016–2026
12.2.1. Vector-based Cas
12.2.2. DNA-free Cas
12.3.Market Value Forecast, by Application, 2016–2026
12.3.1. Genome Engineering
12.3.2. Disease Models
12.3.3. Functional Genomics
12.3.4. Knockdown/activation
12.3.5. Others
12.4.Market Value Forecast, by End-user, 2016–2026
12.4.1. Biotechnology & Pharmaceutical Companies
12.4.2. Academic & Government Research Institutes
12.4.3. Contract Research Organizations
12.5.Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Middle East & Africa CRISPR and Cas Genes Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Product, 2016–2026
13.2.1. Vector-based Cas
13.2.2. DNA-free Cas
13.3.Market Value Forecast, by Application, 2016–2026
13.3.1. Genome Engineering
13.3.2. Disease Models
13.3.3. Functional Genomics
13.3.4. Knockdown/activation
13.3.5. Others
13.4.Market Value Forecast, by End-user, 2016–2026
13.4.1. Biotechnology & Pharmaceutical Companies
13.4.2. Academic & Government Research Institutes
13.4.3. Contract Research Organizations
13.5.Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis, by Company (2015)
14.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.3.1. Synthego
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Thermo Fisher Scientific, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. GenScript
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.4. Addgene
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Merck KGaA (Sigma-Aldrich)
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Integrated DNA Technologies, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Transposagen Biopharmaceuticals, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. OriGene Technologies, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. New England Biolabs
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Dharmacon, a Horizon Discovery Group Co.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Cellecta, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Agilent Technologies
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Applied StemCell, Inc.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
List of Tables
Table 01: Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product, 2016–2026
Table 02: Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application, 2016–2026
Table 03: Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 04: Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product Type, 2016–2026
Table 07: North America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application Type, 2016–2026
Table 08: North America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 09: Europe CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product Type, 2016–2026
Table 11: Europe CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application, 2016–2026
Table 12: Europe CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 13: Asia Pacific CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product Type, 2016–2026
Table 15: Asia Pacific CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application Type, 2016–2026
Table 16: Asia Pacific CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 17: Latin America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product Type, 2016–2026
Table 19: Latin America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application Type, 2016–2026
Table 20: Latin America CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 21: Middle East & Africa CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Product, 2016–2026
Table 23: Middle East & Africa CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by Application, 2016–2026
Table 24 : Middle East & Africa CRISPR and Cas Genes Market Size (US$ Mn) Forecast, by End-user, 2016–2026
List of Figures
Figure 01: Global CRISPR and Cas Genes Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Market Snapshot
Figure 03: Opportunity Map, 2017
Figure 04: Opportunity Map, 2017
Figure 05: Opportunity Map, 2017
Figure 06: Global CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 07: Global CRISPR and Cas Genes Market Value Share, by Product, 2017
Figure 08: Global CRISPR and Cas Genes Market Value Share, by Application, 2017
Figure 09: Global CRISPR and Cas Genes Market Value Share, by End-user, 2017
Figure 10: Global CRISPR and Cas Genes Market Value Share, by Region, 2017
Figure 11: Global CRISPR and Cas Genes Market Value Share, by Product, 2017 and 2026
Figure 12: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vector-based Cas, 2016–2026
Figure 13: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DNA-free Cas, 2016–2026
Figure 14: Global CRISPR and Cas Genes Market Attractiveness Analysis, by Product, 2018–2026
Figure 15: Global CRISPR and Cas Genes Market Value Share, by Application, 2017 and 2026
Figure 16: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Genome Engineering, 2016–2026
Figure 17: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Disease Models, 2016–2026
Figure 18: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Functional Genomics, 2016–2026
Figure 19: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations, 2016–2026
Figure 20: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Functional Genomics, 2016–2026
Figure 21: Global CRISPR and Cas Genes Market Attractiveness Analysis, by Application, 2018–2026
Figure 22: Global CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 23: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Biotechnology & Pharmaceutical Companies, 2016–2026
Figure 24: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Academic & Government Research Institutes, 2016–2026
Figure 25: Global CRISPR and Cas Genes Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations, 2016–2026
Figure 26: Global CRISPR and Cas Genes Market Attractiveness Analysis, by End-user, 2018–2026
Figure 27: Global CRISPR and Cas Genes Market Value Share, by Region, 2017 and 2026
Figure 28: Global CRISPR and Cas Genes Market Attractiveness Analysis, by Region, 2018–2026
Figure 29: North America CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 30: North America CRISPR and Cas Genes Market Value Share, by Country, 2017 and 2026
Figure 31: North America CRISPR and Cas Genes Market Attractiveness, by Country, 2018–2026
Figure 32: North America CRISPR and Cas Genes Market Value Share, by Product Type, 2017 and 2026
Figure 33: North America CRISPR and Cas Genes Market Attractiveness, by Product Type, 2018–2026
Figure 34: North America CRISPR and Cas Genes Market Value Share, by Application Type, 2017 and 2026
Figure 35: North America CRISPR and Cas Genes Market Attractiveness, by Application Type, 2018–2026
Figure 36: North America CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 37: North America CRISPR and Cas Genes Market Attractiveness, by End-user, 2018–2026
Figure 38: Europe CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 39: Europe CRISPR and Cas Genes Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 40: Europe CRISPR and Cas Genes Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 41: Europe CRISPR and Cas Genes Market Value Share, by Product Type, 2017 and 2026
Figure 42: Europe CRISPR and Cas Genes Market Attractiveness, by Product Type, 2018–2026
Figure 43: Europe CRISPR and Cas Genes Market Value Share, by Application, 2017 and 2026
Figure 44: Europe CRISPR and Cas Genes Market Attractiveness, by Application, 2018–2026
Figure 45: Europe CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 46: Europe CRISPR and Cas Genes Market Attractiveness, by End-user, 2018–2026
Figure 47: Asia Pacific CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 48: Asia Pacific CRISPR and Cas Genes Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 49: Asia Pacific CRISPR and Cas Genes Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 50: Asia Pacific CRISPR and Cas Genes Market Value Share, by Product Type, 2017 and 2026
Figure 51: Asia Pacific CRISPR and Cas Genes Market Attractiveness, by Product Type, 2018–2026
Figure 52: Asia Pacific CRISPR and Cas Genes Market Value Share, by Application Type, 2017 and 2026
Figure 53: Asia Pacific CRISPR and Cas Genes Market Attractiveness, by Application Type, 2018–2026
Figure 54: Asia Pacific CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 55: Asia Pacific CRISPR and Cas Genes Market Attractiveness, by End-user, 2018–2026
Figure 56: Latin America CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 57: Latin America CRISPR and Cas Genes Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 58: Latin America CRISPR and Cas Genes Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 59: Latin America CRISPR and Cas Genes Market Value Share, by Product Type, 2017 and 2026
Figure 60: Latin America CRISPR and Cas Genes Market Attractiveness, by Product Type, 2018–2026
Figure 61: Latin America CRISPR and Cas Genes Market Value Share, by Application Type, 2017 and 2026
Figure 62: Latin America CRISPR and Cas Genes Market Attractiveness, by Application Type, 2018–2026
Figure 63: Latin America CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 64: Latin America CRISPR and Cas Genes Market Attractiveness, by End-user, 2018–2026
Figure 65: Middle East & Africa CRISPR and Cas Genes Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 66: Middle East & Africa CRISPR and Cas Genes Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 67: Middle East & Africa CRISPR and Cas Genes Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 68: Middle East & Africa CRISPR and Cas Genes Market Value Share, by Product, 2017 and 2026
Figure 69: Middle East & Africa CRISPR and Cas Genes Market Attractiveness, by Product, 2018–2026
Figure 70: Middle East & Africa CRISPR and Cas Genes Market Value Share, by Application, 2017 and 2026
Figure 71: Middle East & Africa CRISPR and Cas Genes Market Attractiveness, by Application, 2018–2026
Figure 72: Middle East & Africa CRISPR and Cas Genes Market Value Share, by End-user, 2017 and 2026
Figure 73: Middle East & Africa CRISPR and Cas Genes Market Attractiveness, by End-user, 2018–2026
Figure 74: Thermo Fisher Scientific Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 75: Thermo Fisher Scientific Inc. Breakdown of Net Sales, by Region, 2017
Figure 76: Thermo Fisher Scientific Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 77: Thermo Fisher Scientific Inc. R&D Expense (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure 78: GenScript Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 79: GenScript Breakdown of Net Sales, by Region, 2017
Figure 80: GenScript Breakdown of Net Sales, by Business Segment, 2017
Figure 81: GenScript R&D Expense (US$ Mn) and Selling and Distribution (US$ Mn), 2016–2017
Figure 82: Merck KGaA (Sigma Aldrich) Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 83: Merck KGaA (Sigma Aldrich) Breakdown of Net Sales, by Region, 2017
Figure 84: Merck KGaA (Sigma Aldrich) Breakdown of Net Sales, by Business Segment, 2017
Figure 85: Merck KGaA (Sigma Aldrich) Research & Development Market Share (%), by Business Segment, 2017
Figure 86: Agilent Technologies Breakdown of Net Sales, by Region, 2017
Figure 87: Agilent Technologies Breakdown of Net Sales (US$ Mn), by Segment, 2017
Figure 88: Agilent Technologies Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
CRISPR and Cas Genes Market
